Deep vein thrombosis
Deep vein thrombosis (DVT) is the formation of a blood clot in the body’s deep and larger veins, such as in the calves and thighs. In the UK, 1 in every 1,000 people will develop DVT1, though it becomes increasingly common with ageing and other factors, such as inactivity. Whilst DVT is in itself not life-threatening, it can cause extreme pain and swelling and lead to potentially serious complications, such as pulmonary embolism.
Although DVT can be treated with anticoagulation medicines, which work by making it harder for the blood to clot, it is more important to inform people of DVT risk factors in order to encourage its prevention. That is why LEO Pharma UK/IE is committed to raising awareness of these conditions, helping patients with DVT and/or PE or those at risk of developing venous thromboembolism (VTE). LEO Pharma offers Health Care Professionals a wide range of materials with information to help their VTE patients to understand their condition and treatment.
LEO Pharma has also partnered with the charity AntiCoagulation UK (ACUK) to raise awareness of the increased risk of blood clots in people living with cancer, known as cancer associated thrombosis (CAT).
“Cancer Associated Thrombosis (CAT) is a devastating condition that causes up to 4000 deaths each year. In order to raise awareness of CAT and help prevent these deaths everyone involved in the cancer patient pathway must share responsibility for raising awareness of CAT amongst cancer patients.
Anticoagulation UK is delighted to be working in partnership with LEO Pharma to develop a range of materials that will alert cancer patients to what signs and symptoms of CAT to look out for, educational materials for health care professionals to enable them to support their patients and a comprehensive website.
Our partnership is working at all levels and has the support of the All Party Parliamentary Thrombosis Group who has produced two reports on the prevalence of CAT.”
– Eve Knight, Anticoagulation UK
1 APPTG Venous Thromboembolism (VTE) In Cancer Patients Oct 16, page 3